Get the Stockscreener App
46.71
1.25%
-0.59
After Hours:
46.54
-0.17
-0.36%
Moderna Inc stock is traded at $46.71, with a volume of 4.82M.
It is down -1.25% in the last 24 hours and down -5.06% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$47.30
Open:
$47.675
24h Volume:
4.82M
Relative Volume:
0.60
Market Cap:
$18.53B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-5.734
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
-0.91%
1M Performance:
-5.06%
6M Performance:
+98.26%
1Y Performance:
+67.78%
1-Day Range:
$45.78
$47.73
1-Week Range:
$43.68
$48.40
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
46.71 | 18.77B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna stands as the best performing large-cap healthcare stock YTD - MSN
FDA halts publication of studies on COVID, shingles vaccines - Seeking Alpha
Brookline Capital Markets Weighs in on Moderna Q2 Earnings - MarketBeat
Non-covid mRNA Vaccine and Therapeutics Market Supply Chain Analysis and Revenue Forecast 2026 to 2035 - openPR.com
Moderna (MRNA) Receives a Buy from Piper Sandler - The Globe and Mail
Sigma Planning Corp Makes New $907,000 Investment in Moderna, Inc. $MRNA - MarketBeat
Abbas Hussain Sells 5,682 Shares of Moderna (NASDAQ:MRNA) Stock - MarketBeat
Moderna director Abbas sells $264,951 in shares - Investing.com
Sandra Horning at Moderna (NASDAQ: MRNA) gains 16,233 shares via RSU vesting - Stock Titan
Director Rubenstein acquires 8,116 Moderna (NASDAQ: MRNA) shares - Stock Titan
Tax-driven stock sale by Moderna (MRNA) director after RSU vesting - Stock Titan
Director at Moderna (MRNA) receives 16,233 shares as RSUs vest - Stock Titan
Director at Moderna (NASDAQ: MRNA) receives 12,174 vested shares - Stock Titan
MRNA Maintained by RBC Capital -- Price Target Raised to $38.00 - GuruFocus
Moderna (MRNA) director converts 4,058 RSUs into common stock - Stock Titan
Moderna shares rise as investors revisit Q1 results, pipeline milestones, and fresh price-target bumps - Quiver Quantitative
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era - Yahoo Finance
UBS Adjusts Price Target on Moderna to $45 From $36, Maintains Neutral Rating - marketscreener.com
Mitsubishi UFJ Trust & Banking Corp Boosts Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals - The Globe and Mail
Brokers Issue Forecasts for Moderna FY2029 Earnings - MarketBeat
MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds - Yahoo Finance
Moderna’s Stock Rises in 2026 as International COVID-19 Vaccine Sales Offset U.S. Decline - geneonline.com
Moderna’s strong vaccine sales outside US far surpass estimates - The Boston Globe
Moderna (MRNA) Is Down 10.6% After Q1 Loss Widened On Settlement And EU Vaccine Wins – Has The Bull Case Changed? - Yahoo Finance
ProShares Ultra S&P 500 Equal Weight's Moderna Inc(MRNA) Holding History - GuruFocus
Vanguard Group Inc. Purchases 399,487 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q1 2026 Earnings Call Transcript - Insider Monkey
A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals - Yahoo Finance
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges By GuruFocus - Investing.com Canada
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges - GuruFocus
Moderna (MRNA) Reports Strong Q1 2026 Performance with $400 Million Revenue - GuruFocus
Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings - Moomoo
Moderna, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Legal settlement drives Q1 2026 loss at Moderna (NASDAQ: MRNA) - Stock Titan
Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales - The Economic Times
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. - Barron's
Sector Update: Health Care Stocks Softer Friday Afternoon - Moomoo
Moderna, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MRNA) 2026-05-01 - Seeking Alpha
Moderna’s first quarter 2026 sales well ahead of estimates - The Pharma Letter
RBC Capital raises Moderna stock price target on Q1 beat By Investing.com - Investing.com Canada
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales - The Globe and Mail
Moderna sees revenue bump from international COVID vaccine sales - BioPharma Dive
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings - Proactive financial news
[144] Moderna, Inc. SEC Filing - Stock Titan
BofA raises Moderna stock price target to $32 on Q1 beat - Investing.com
Moderna Sales Triple To $389 Million As Shares Rise 5.4% - GuruFocus
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook - Seeking Alpha
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):